Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AvaALL: Bevacizumab beyond progression in advanced non-squamous NSCLC
NCT01351415Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2011
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) comparing Bevacizumab + Standard of Care with Standard of Care (2 arms). Primary endpoint: Overall Survival up to 5 years. Started Jun 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01351415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01351415.